IM MEDICAL LTD (IMI)

name changed to Babylon Pump & Power Limited

The company has received $4.5 million under the public offer and the priority offer. All resolutions at the 1 November 2017 AGM in relation to the acquisition were overwhelmingly supported.

we understand that on or about this date the company consolidated its shares 1 for 20

The company releases a notification of reorganisation of capital - consolidation. Shareholders get 1 share for every 20 presently owned.

The company releases the results of its meeting.

The company releases the chairman's address to shareholders at the AGM.

The company lodges its Appendix 4C - quarterly report.

The company has lodged a prospectus to raise up to $6.0 million. The offer is partially underwritten by Patersons Securities to the minimum subscription of $4,000,000.

The AGM of the company will be held at Level 15, 333 Collins Street, Melbourne, Victoria on 1 November 2017 at 11:00am (AEDT).

IMI has exercised its option to acquire all of the issued capital of Babylon Operations.

The company lodges its Annual Report to shareholders.

The company lodges its Preliminary Final Report.

The company lodges its Appendix 4C - quarterly report.

The company releases a Babylon Operations P/L Progress Report.

The company provides a funding and strategy update. The directors of the company express their gratitude for the recently completed rights issue, the purpose of which is to repay creditors and provide working capital in preparation for the proposed acquisition of Babylon Operations. Following completion of the rights issue, Chesapeake Capital is welcomed as a substantial shareholder. As for Babylon, after raising approximately $1m in new capital, Babylon has secured a leased operations facility strategically located in Forrestfield, Western Australia.

The company is pleased to announce the successful completion of its underwritten 3 for 8 non-renounceable entitlement offer priced at $0.001 which closed on 5th May 2017.

The company releases its Appendix 4C - quarterly report.

The company issues a response to ASX Appendix 3Y Query.

The company issues a prospectus for a non-renounceable pro rata offer of up to 498,237,396 shares at an issue price of $0.001 each on the basis of 3 shares for every 8 shares held at the record date, together with one free attaching option for every share subscribed for.

The company releases an Investor Presentation.

The company lodges its Half Yearly Report and Accounts.

The company proposes to undertake a pro-rata non-renounceable entitlements issue on the basis of 3 new fully paid ordinary shares in the company for every 8 existing shares held by eligible shareholders at an issue prie of $0.002 per share, to raise approximately $0.5 million, together with one free attaching option for every share issued.

The company's subsidiary, IMI Zinc Exploration, has received the final payment of $200,000 from Rox Resources Limited under the 14 December 2016 Settlement Agreement. Based on the cost reimbursement, Rox and IMI Zinc agreed to release each other from all claims in relation to the IMI offer.

The company lodges its Appendix 4C - quarterly report.

THe company's subsidiary, IMI Zinc Exploration, has reached an agreement with Rox Resources for the reimbursement of costs incurred by IMI Zinc in connection with an offer made by IMI Zinc on 18 July 2016 to acquire Rox's interest in the Reward Zinc Project. Under the agreement, Rox will pay to IMI Zinc a total sum of $220,000 for IMI Zinc's reasonable expenses in respect of the IMI Offer. The payment comprises $20,000 cash payable immediately and $200,000 cash payable either on settlement by Rox of the sale of its interest in the Reward Zinc Project, or when Rox completes a significant (>$500,000) capital raising, whichever occurs first.

The company releases the Results of Meeting.

The company releases the Chairman's Address to Shareholders.

The company lodges its Annual Report to shareholders.

The company lodges its Half Yearly Report and Accounts.

The Annual General Meeting of the Company will be held at Patersons Securities Limited, Level 15, 333 Collins Street, Melbourne, Victoria on 30 November 2016 at 11:00am (AEDT).

The company releases its Appendix 4C - quarterly report.

On 17 August 2016 Rox announced that it has accepted a revised offer from Marindi for the Reward JV and has entered into an exclusivity regime with Marindi. IMI considers the actions of Rox are in breach of the terms of the exclusivity agreement currently in place with IMI, and IMI reserves its rights in relation to the exclusivity agreement. The Directors of IMI are disappointed with the outcome of the offer process. IMI will now consider its options and will continue to look for a suitable business or project for future investment.

The company notes the announcement made today by Rox Resources Ltd and confirms that it made a binding but confidential offer for Rox's 30% interest in the Reward Joint Venture with Teck Australia on Friday, 5 August 2016 for a total consideration of A$16 million. The Marindi Offer is open for acceptance until 5.00pm AWST, 9 August 2016.

After close of trade on Friday 5 August 2016, Rox received an unsolicited offer from Marindi Metals Ltd for the Company's interest in the Reward project. The New Offer is in the form of a binding Heads of Agreement for a purported value of $16 million. The New Offer is conditional upon a number of matters, including completion of a fundraising by Marindi, and unless accepted or extended, will expire at the close of business today.

The company has raised $330,000 before costs from the issue of a Converting Loan to sophisticated investors introduced by Patersons Securities Limited. The funds raised under the Converting Loan will be used to fund transaction documentation costs and provide working capital.

The company lodges its Appendix 4C - quarterly report.

Rox Resources Limited is pleased to announce that IMI Zinc Exploration Pty Ltd, a wholly owned subsidiary of IM Medical Limited, has today made an offer to acquire Rox's interest in the Reward zinc-lead project in the Northern Territory. Subject to Rox entering into an Exclusivity Agreement, which Rox has agreed to do, the Offer remains open for acceptance until 17 August 2016. The Exclusivity Period allows Rox 30 days to complete due diligence on the $14.8 million Offer from IZE, which comprises $2.0 million payable in cash and the issue of $12.8 million worth of shares in IZE's parent company, IMI.

The company lodges its quarterly report.

The company lodges its quarterly report.

The ASX has advised the company that, as a result of the Company having no main undertaking and an insufficient level of operations for an extended period of time, the ASX will not reinstate trading in the Company's securities until such time as the Company has completed a transaction and re-complied with Chapters 1 and 2 of the Listing Rules. As a result, the mandate for the recently announced placement to raise $1,000,000 at $0.00075 per share has been terminated on the basis that the participants were expecting to receive quoted securities in a non-suspended company.

The securities of IM Medical Limited (the "Company") will be suspended from quotation immediately at the request of the Company pending the release of an announcement in relation to the capital raising announced on 18 December 2015. Security Code: IMI

The securities of IM Medical Limited (the "Company") will be reinstated to quotation immediately, following the release of the response to an ASX query letter today and the Audited Full Year Accounts for the period ended 30 June 2015 on 1 October 2015. Security Code: IMI

The company issues a response to ASX query letter.

The company lodges its annual financial report for the year ended 30 June 2015.

The securities of the company will be suspended from Official Quotation from the commencement of trading today 1 October 2015 following failure to lodge their Full Year Accounts for the period ended 30 June 2015 in accordance with ASX Listing Rules.

we understand that on or about this date the company made an in specie distribution of 1 share in Capitol Health for every 16.99 shares in the company

the suspension of trading in the securities of IM Medical Limited (the "Company") will be lifted prior to the commencement of trading on Tuesday 8 November 2011 following the Company's announcement confirming that despatch of new holding statements has occurred in relation to the entitlement issue undertaken by the Company

company announces its entitlement offer has closed oversubscribed

the Annual General Meeting of the Company will be held at The Quest Beaumont Kew, 7 Studley Park Road, Kew on November 23, 2011 at 2.00 pm (AEDT)

company says it has received overwhelming shareholder approval for the proposed Entitlement Issue at the Company's general meeting today. The Company is now working with the appointed lead manager, Patersons Securities to complete the Entitlements Issue

lodges annual report

IM Medical Ltd director Mark Scott sold his 56,447,604 shares (51.08%) on September 20, 2011. He holds 88,747,603 options

company says that "following completion of the recapitalisation and restructure, the Company intends to investigate acquisition and investment opportunities to restore Shareholder value. The Directors expect to consider opportunities across a range of sectors which may take the Company away from its medical services focus"

company releases a prospectus for its offer to raise capital on the basis of 6 shares for every one held at an issue price of 0.5 cents

company encloses a Notice of Meeting in respect to a General Meeting of Shareholders to be held at The Quest Beaumont Kew on 21 October 2011 at 2.00pm - the purpose of the General Meeting is to seek shareholder approval for a non-renounceable Entitlement Issue to raise up to $3.3 million before costs to recapitalise the Company and pay out all creditors

announces an offer to shareholders to raise $3.3m

following the approval by shareholders at the General Meeting held on August 16, 2011of Resolution 2 Share Consolidation on the basis that every fifty (50) shares be consolidated into one (1) share and that all options on issue be adjusted in accordance the terms and conditions of the options. The Company now reports that documentation will be despatched to share and option holders today

at the meeting on 16 August, Motions 1 & 4 were withdrawn before the Meeting, motion 3 was rejected and the remaining motions carried as ordinary resolutions on a poll

some shareholders have received a letter from Dr Laurie Williams seeking their proxies in order to vote against the resolutions that will be considered at the Company's General Meeting on 16 August 2011 - current Directors do not agree with the statements made by Dr Williams in his letter - current Directors do not recommend you give your proxies to Dr Williams - if you have already done so, you are entitled to resubmit your proxy

company responds to ASX queries following the release of the Company's Quarterly Report in the form of Appendix 4C for the period ending 30 June 2011 lodged by the Company with ASX on 29 July 2011 ("Appendix 4C") and the Company's Half Year Report for the period ending 31 December 2010 lodged by the Company with ASX on 4 August 2011

lodges Half Yearly Report and Accounts

circulates a Notice of Meeting in respect to a General Meeting of Shareholders to be held at The Quest Beaumont Kew on August 16 2011 at 2.00pm - the proposed share consolidation will be amended to a 1 for 50 basis (in other words existing shareholders - if they do not take up an offer of shares - will end up owning 2% of the company)

announces a recapitalisation and restructure initiative whereby the Company: (a) has raised $750,000 by way of Converting Loans which will convert into shares and options in the Company (Converting Loans); (b) intends to undertake a 1 for 15 share consolidation%(Consolidation); and (c) intends to undertake an underwritten pro rata entitlement offer to raise a further $1.85 million before costs

IM Medical Limited (IMI) is pleased to announce it has signed a Heads of Agreement with Capitol Health Limited in relation to the acquisition by Capitol of the Radiology operations of IMI in exchange for the issue of 45.56 million CAJ ordinary shares to IMI and up to $600,000 in cash, payable in 3 tranches within 2 years based on the performance of the IMI Radiology operations

The Company has received from the major shareholder a Notice to convene a meeting to remove all Directors from the Board of IMI. Notice of the meeting will be sent out shortly

suspended from quotation following failure to lodge its half yearly financial report

shares reinstated to quotation

the securities will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement

name changed from Integra Medical Imaging Limited